The SUMMIT10 trial in 2018 found that neratinib prolonged median progression-free survival rate in a cohort of 26 NSCLC patients with HER2 mutations, but only one patient achieved a response that meets the RECIST criteria11. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.